DCIS - Our Science-Discovery-Development-Validation | DCISionRT

PublicationsPrelude2018-11-02T15:24:03-05:00

Bremer, TM et al. A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk, Clinical Cancer Research 2018, Published Online 12/01/2018

December 1st, 2018|

Wärnberg, F et al. A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS), SABCS 2017; Abstract: 851741

December 13th, 2017|

Bremer, TM et al. MBCC 2017; Poster: Utility of the DCIS Biological Risk Profile for Predicting Recurrence Risk Compared to Standard Clinicopathologic Factors

April 12th, 2017|

Bremer, TM et al. MBCC 2017; Abstract: Utility of the DCIS Biological Risk Profile for Predicting Recurrence Risk Compared to Standard Clinicopathologic Factors

April 12th, 2017|

Bremer, TM et al. SABCS 2016; Publication Number: S5-01 – AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S5-01

December 9th, 2016|

Bremer, TM et al. A multi-marker test for invasive risk post DCIS treated with BCS +/- RT, ASCO 2016; Abstract 1019

April 30th, 2016|

Bremer, TM et al. A multi-marker test for recurrence risk after BCS +/- RT for DCIS, MBCC 2016; Abstract 364

January 21st, 2015|

Linke, SP et al. Validation of a multi-marker test that predicts recurrence in patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS), SABCS 2014; Abstract 851032

March 12th, 2014|

Kerlikowski, K et al. Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis J Natl Cancer Inst 2010; 102(9)627-37

September 16th, 2010|

Gauthier, ML et al. Abrogated Response to Cellular Stress Identifies DCIS Associated with Subsequent Tumor Events and Defines Basal-like Breast Tumors, Cancer Cell 2007; 12(5)479-91

May 5th, 2007|